Cat. #153511
Anti-CD20 [2H7]
Cat. #: 153511
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD20
Class: Monoclonal
Application: ELISA ; FACS ; IHC ; WB
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Clonegene LLC
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD20 [2H7]
- Alternate name: B-lymphocyte antigen CD2
- Research fields: Cancer;Cell biology;Immunology
- Clone: 2H7
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; FACS ; IHC ; WB
- Description: B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and non-lymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants that encode the same protein. CD20 is the target of the monoclonal antibodies (mAb) rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemia. It has been shown that inhibition of BCR signalling by ibrutinib affects the expression of CD20 and the efficacy of anti-CD20 antibodies.
- Immunogen: Native CD20
- Isotype: IgG2b
Target Details
- Target: CD20
- Target background: B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and non-lymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants that encode the same protein. CD20 is the target of the monoclonal antibodies (mAb) rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemia. It has been shown that inhibition of BCR signalling by ibrutinib affects the expression of CD20 and the efficacy of anti-CD20 antibodies.
Applications
- Application: ELISA ; FACS ; IHC ; WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C